Society for NeuroOncology

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve recurrent glioblastoma

Society for NeuroOncology

Phase 1/2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed, MGMT-unmethylated glioblastoma

Society for NeuroOncology

Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of diffuse intrinsic pontine glioma (DIPG)

Society for NeuroOncology

VAL-083 inhibits proliferation of a panel of eight glioblastoma stem cells: Downregulation of BRD4 as a novel anti-neoplastic mechanism

AACR Annual Meeting 2018

Dianhydrogalactitol (VAL-083) has a distinct mechanism of action that suggests combination with PARP inhibitors as an effective therapeutic strategy

AACR Annual Meeting 2018

Dianhydrogalactitol (VAL-083) has the potential to overcome major challenges in the treatment of DIPG

AACR Annual Meeting 2018

An open-label, biomarker driven, Phase 1/2 study of dianhydrogalactitol (VAL-083) with radiation therapy in patients with newly diagnosed MGMT-unmethylated GBM

AACR Annual Meeting 2018

Phase 2 study of dianhydrogalactitol (VAL-083) in patients with bevacizumab-naïve recurrent glioblastoma, MGMT-unmethylated

Society for NeuroOncology

Dianhydrogalactitol (VAL-083) overcomes chemoresistance in pediatric malignant brain tumors and displays synergy with topoisomerase inhibitors

Society for NeuroOncology

The distinct cytotoxic mechanism of dianhydrogalactitol (VAL-083) overcomes chemoresistance and provides new opportunities for combination therapy in the treatment of glioblastoma